Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarcHER
2015-003400-24Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Abemaciclib + trastuzumab + fulvestrant, Abemaciclib + trastuzumab and Physician's choice chemotherapy + trastuzumab (3 arms). Primary endpoint: Progression-free survival. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-003400-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003400-24.